All In Biotech

NDA 219990 · Viatris Specialty

Gwyn Lo

Ethinyl Estradiol, Norelgestromin · Transdermal · Progestin; Estrogen

Last checked: Nov 20, 2026Latest source record: Jul 28, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2026

Jul 28, 2026

Approved uses

1

Original approval plus efficacy supplements

Registered trials

501

113 Phase 3, 20 recruiting

FAERS reports

1

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS and CONTRAINDICATED IN WOMEN WITH A BMI ≥ 30 KG/M 2 Cigarette Smoking and Serious Cardiovascular Events Cigarette smoking increases the risk of serious cardiovascular events from hormonal contraceptive use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, CHCs, including GWYN LO, are contraindicated in women who are over 35 years of age and smoke [see Contraindications (4) and Warnings and Precautions (5.1) ] . Contraindicated in Women with a BMI ≥ 30 kg/m 2 GWYN LO is contraindicated in women with a BMI ≥ 30 kg/m 2 . The risk of VTE may be greater with GWYN LO in women with a BMI > 30 kg/m 2 compared to women with a lower BMI [see Contraindications (4) and Warnings and Precautions (5.1) ] . WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR...

What it is approved for

From the label in effect Jul 6, 2026.

GWYN LO is indicated for the prevention of pregnancy in women with a body mass index (BMI) < 30 kg/m 2 for whom a combined hormonal contraceptive is appropriate. GWYN LO is a progestin/estrogen combination hormonal contraceptive (CHC), indicated for the prevention of pregnancy in women with a BMI < 30 kg/m 2 for whom a combined hormonal contraceptive is appropriate. ( 1 )

Mechanism: Combination hormonal contraceptives lower the risk of becoming pregnant primarily by suppressing ovulation.

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 28, 2026 Original approval · Type 5 - New Formulation or New Manufacturer Letter
1 products under this application
  • GWYN LO · ETHINYL ESTRADIOL 0.02MG/24HR; NORELGESTROMIN 0.22MG/24HR · SYSTEM, TRANSDERMAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ethinyl Estradiol" as an intervention, any sponsor and status, largest first.

All 501 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1
  • impaired quality of life1
  • inappropriate schedule of product administration1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20241

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,068 on PubMed

Sponsor: Viatris Specialty

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.